Carmell (CTCX) Stock Price, News & Analysis

Company Overview

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $0.17 to $0.18
• 50-Day Range: $0.17 to $0.58
• 52-Week Range: $0.17 to $2.94
• Volume: 631,447 shs
• Average Volume: 3.06 million shs
• Market Capitalization: $3.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Carmell Stock Analysis - MarketRank™

Carmell scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Carmell.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Carmell has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.60% of the float of Carmell has been sold short.

Short Interest Ratio / Days to Cover

Carmell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carmell has recently decreased by 66.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carmell does not currently pay a dividend.

Dividend Growth

Carmell does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.60% of the float of Carmell has been sold short.

Short Interest Ratio / Days to Cover

Carmell has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carmell has recently decreased by 66.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Carmell has a news sentiment score of -0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Carmell this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for CTCX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carmell insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.00% of the stock of Carmell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 24.22% of the stock of Carmell is held by institutions.

CTCX Stock Analysis - Frequently Asked Questions

How have CTCX shares performed this year?

Carmell's stock was trading at $0.2791 at the beginning of 2025. Since then, CTCX stock has decreased by 39.9% and is now trading at $0.1678.
View the best growth stocks for 2025 here.

Who are Carmell's major shareholders?

Carmell's top institutional shareholders include Citadel Advisors LLC (0.90%) and Antara Capital LP (0.48%). Insiders that own company stock include Rajiv Shukla, Kathryn Gregory, Patrick A Sturgeon, Richard A Upton, Scott M Frisch, Gilles Spenlehauer, Bryan J Cassaday and Randolph W Hubbell.
View institutional ownership trends.

How do I buy shares of Carmell?

Shares of CTCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Carmell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Carmell investors own include Sangamo Therapeutics (SGMO), Abrdn Asia-Pacific Income Fund (FAX), MSP Recovery (LIFW), MSP Recovery (LIFW), Meta Platforms (META), NVIDIA (NVDA) and Blue Owl Capital (OBDC).

Company Calendar

• Today: 3/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CTCX
• CIK: 1842939
• Web: www.carmellrx.com
• Phone: 412-894-8248
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,440,000.00
• Net Margins: N/A
• Pretax Margin: -29,527.27%
• Return on Equity: -217.50%
• Return on Assets: -50.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.31
• Quick Ratio: 0.29

Sales & Book Value

• Annual Sales: $32,839.00
• Price / Sales: 106.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.07 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 20,905,000
• Free Float: 14,843,000
• Market Cap: $3.51 million
• Optionable: Not Optionable
• Beta: 0.51